Combined gemfibrozil (peroxisome proliferator-activated receptor alpha agonist) with reduced steroid dose gives a similar management picture as the full steroid dose in a rat adjuvant-induced arthritis model

References

• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–61. doi:10.1038/nature01661
   PubMed Web of Science ®Google Scholar
• Koufany M, Jouzeau JY, Moulin D. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis. Biomed Mater Eng. 2014;24:81–8.
   PubMed Web of Science ®Google Scholar
• Roman-Blas JA, Jimenez SAMD. Review NF- k B as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthr. Cartil. 2006.
   Google Scholar
• Amin AR, Islam ABMMK. Genomic Analysis and Differential Expression of HMG and S100A Family in Human Arthritis: Upregulated Expression of Chemokines, IL-8 and Nitric Oxide by HMGB1. DNA Cell Biol. 2014;33(8):550–65.
   PubMed Web of Science ®Google Scholar
• Andersson U, Erlandsson-Harris H. HMGB1 is a potent trigger of arthritis. J Intern Med. 2004;255(3):344–50.
   PubMed Web of Science ®Google Scholar
• Liu AH, Wu YT, Wang YP. MicroRNA-129-5p inhibits the development of autoimmune encephalomyelitis-related epilepsy by targeting HMGB1 through the TLR4/NF-kB signaling pathway. Brain Res Bull. 2017;132:139–49.
   PubMed Web of Science ®Google Scholar
• Versini M, Jeandel P, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13(9):981–1000.
   PubMed Web of Science ®Google Scholar
• Loredo-Pérez Aleyda A, Montalvo-Blanco CE, Hernández-González LI, Anaya-Reyes M, Valle-Laisequilla CFD, Reyes-García JG. High-fat diet exacerbates pain-like behaviors and periarticular bone loss in mice with CFA-induced knee arthritis. Obesity. 2016;24(5):1106–15.
   PubMed Web of Science ®Google Scholar
• Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther. 2006;110(3):371–85.
   PubMed Web of Science ®Google Scholar
• van Everdingen AA, Jacobs JWG, Siewertsz van Reesema DR, Bijlsma JWJ. Low-dose prednisone for early active rheumatoid arthritis: should you use it? Ann Intern Med. 2002;136(1):1–12.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2016 update. Ann Rheum Dis. 2017;76(6):960–77.
   PubMed Web of Science ®Google Scholar
• Hoes JN, Jacobs JWG, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560–7.
   PubMed Web of Science ®Google Scholar
• Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and refeeding. Endocrinology 2001;142(10):4195–202.
   PubMed Web of Science ®Google Scholar
• Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010;120(2–3):69–75.
   PubMed Web of Science ®Google Scholar
• Mohagheghi F, Khalaj L, Ahmadiani A, Rahmani B. Gemfibrozil pretreatment affecting antioxidant defense system and inflammatory, but not Nrf-2 signaling pathways resulted in female neuroprotection and male neurotoxicity in the rat models of global cerebral ischemia-reperfusion. Neurotox Res. 2013;23(3):225–37.
   PubMed Web of Science ®Google Scholar
• Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharma. 2016;7(2):27–31.
   PubMedGoogle Scholar
• Fereidoni M, Ahmadiani A, Semnanian S, Javan M. An accurate and simple method for measurement of paw edema. J Pharmacol Toxicol Methods. 2000;43(1):11–14.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT. Method 2001;25(4):402–8.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Laverty S, Kraus VB, Aigner T. Basic methods in histopathology of joint tissues. Osteoarthr Cartil. 2010;18:S113–S6.
   PubMed Web of Science ®Google Scholar
• Bendele AM. Animal models of rheumatoid arthritis. Eur J Immunol. 2009;1:377–85.
   Google Scholar
• Nakamachi Y, Ohnuma K, Uto K, Noguchi Y, Saegusa J, Kawano S. MicroRNA-124 inhibits the progression of adjuvant-induced arthritis in rats. Ann Rheum Dis. 2015;1–8.
   Google Scholar
• Yang H. The cytokine activity of HMGB1. J Leukoc Biol. 2005;78(1):1–8.
   PubMed Web of Science ®Google Scholar
• Harris HE, Andersson U, Pisetsky DS. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012;8(4):195–202.
   PubMed Web of Science ®Google Scholar
• Lotze MT, Tracey KJ. high-mobility group box 1 protein (hmgb1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4):331–42.
   PubMed Web of Science ®Google Scholar
• Qin Y, Chen Y, Wang W, Wang Z, Tang G, Zhang P, et al. HMGB1–LPS complex promotes transformation of osteoarthritis synovial fibroblasts to a rheumatoid arthritis synovial fibroblast-like phenotype. Cell Death Dis. 2014;5(2):e1077.
   PubMedGoogle Scholar
• Alghasham A, Rasheed Z. Therapeutic targets for rheumatoid arthritis: Progress and promises. Autoimmunity. 2014;47(2):77–94.
   PubMed Web of Science ®Google Scholar
• Ying S, Xiao X, Chen T, Lou J. PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1. PPAR Res. 2016;2016:1.
   Web of Science ®Google Scholar
• Mcinnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.
   PubMed Web of Science ®Google Scholar
• Ostrakhovitch EA, Afanas IB. Oxidative stress in rheumatoid arthritis leukocytes: Suppression by rutin and other antioxidants and chelators. Biochemical Pharmacology. 2001;62(6):743.
   PubMed Web of Science ®Google Scholar
• Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. Nat Publ Gr. 2014;
   Google Scholar
• Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: Regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol. 2003;85(2–5):267–73.
   PubMed Web of Science ®Google Scholar
• Doss HM, Ganesan R, Rasool M. Trikatu, an herbal compound ameliorates rheumatoid arthritis by the suppression of inflammatory immune responses in rats with adjuvant-induced arthritis and on cultured fibroblast like synoviocytes via the inhibition of the NFκB signaling pathway. Chem Biol Interact. 2016;258:175–86.
   PubMed Web of Science ®Google Scholar
• Clockaerts S, Bastiaansen-Jenniskens YM, Feijt C, Verhaar JAN, Somville J, De Clerck LS, et al. Peroxisome proliferator activated receptor alpha activation decreases inflammatory and destructive responses in osteoarthritic cartilage. Osteoarthr Cartil. 2011;19(7):895–902.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:323–30.
   PubMed Web of Science ®Google Scholar
• Gkretsi V, Simopoulou T, Tsezou A. Lipid metabolism and osteoarthritis: Lessons from atherosclerosis. Prog Lipid Res. 2011;50(2):133–40.
   PubMed Web of Science ®Google Scholar
• Dahaghin S, Bierma-Zeinstra SMA, Koes BW, Hazes JMW, Pols HAP. Do metabolic factors add to the effect of overweight on hand. Ann Rheum Dis. 2007;66(7):916–20. .
   PubMed Web of Science ®Google Scholar
• Sowers MR, Karvonen-Gutierrez CA. The evolving role of obesity in knee osteoarthritis. Curr Opin Rheumatol. 2010;22(5):533–7.
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Mccann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation. J Clin Invest. 2003;112(12):1796.
   PubMed Web of Science ®Google Scholar
• Lemberger T, Saladin R, Vázquez M, Assimacopoulos F, Staels B, Desvergne B, et al. Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem. 1996;271(3):1764–9.
   PubMed Web of Science ®Google Scholar
• Shirinsky IV, Shirinsky VS. Targeting nuclear hormone receptors: Ppar agonists as potential disease-modifying drugs for rheumatoid arthritis. Int J Rheumatol. 2011;2011:1.
   Google Scholar
• Riccardi L, Mazzon E, Bruscoli S, Esposito E, Crisafulli C, Di Paola R, et al. Peroxisome proliferator-activated receptor-α modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice. SHOCK. 2009;31(3):308–16.
   PubMed Web of Science ®Google Scholar
• Bougarne N, Paumelle R, Caron S, Hennuyer N, Mansouri R, Gervois P, et al. PPARα blocks glucocorticoid receptor α-mediated transactivation but cooperates with the activated glucocorticoid receptor α for transrepression on NF-kB. Pnas 2009;106(18):7397–402.
   PubMed Web of Science ®Google Scholar